Car­lyle Group in­jects $260M in­to a lead­ing car­dio play­er in Chi­na, grab­bing a seat at the deals ta­ble

The Car­lyle Group is in­vest­ing $260 mil­lion to grab a mi­nor­i­ty stake in Shen­zhen Salu­bris Phar­ma­ceu­ti­cal, a sto­ried gener­ic mak­er that’s in­creas­ing­ly in­vest­ing in new drug R&D.

The cash is good for a 5% stake in Shen­zhen-list­ed Salu­bris, giv­ing the pri­vate eq­ui­ty play­er ac­cess to a port­fo­lio of treat­ments and de­vices in the car­dio­vas­cu­lar, on­col­o­gy and an­ti-in­fec­tive ar­eas. As the Chi­nese gov­ern­ment’s re­im­burse­ment re­forms spur con­sol­i­da­tion in the gener­ic drug mar­ket, some play­ers are poised to gain mar­ket share, Car­lyle not­ed in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER